Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rampling

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiationN Doherty, S L Hancock, S Kaye, et al.
Gene Therapy|June 14, 2000
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaR Rampling, G Cruickshank, V Papanastassiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodiesA A Epenetos, A J Munro, S Stewart, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 7, 2003
Don't wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compressionP Levack, J Graham, D Collie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
British Journal of Cancer|January 19, 2000
Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat modelR J Mairs, C L Wideman, W J Angerson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseM Brada, K Hoang-Xuan, R Rampling, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiationN Doherty, S L Hancock, S Kaye, et al.
Gene Therapy|June 14, 2000
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaR Rampling, G Cruickshank, V Papanastassiou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1987
Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodiesA A Epenetos, A J Munro, S Stewart, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 7, 2003
Don't wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compressionP Levack, J Graham, D Collie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeC Twelves, M Campone, B Coudert, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
British Journal of Cancer|January 19, 2000
Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat modelR J Mairs, C L Wideman, W J Angerson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapseM Brada, K Hoang-Xuan, R Rampling, et al.
Pageof 6